SYRE
NASDAQSpyre Therapeutics Inc.
News25/Ratings12
News · 26 weeks64+22%
2026-04-192026-10-11
Mix3090d
- Insider9(30%)
- Other9(30%)
- SEC Filings7(23%)
- Analyst3(10%)
- Offering2(7%)
Latest news
25 items- ANALYSTUBS initiated coverage on Spyre Therapeutics with a new price targetUBS initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $120.00
- SECSEC Form 8-K filed by Spyre Therapeutics Inc.8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- SECSEC Form 424B5 filed by Spyre Therapeutics Inc.424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRSpyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockWALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other
- SECSEC Form 424B5 filed by Spyre Therapeutics Inc.424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRSpyre Therapeutics Announces Proposed Public Offering of its Common StockWALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering under the same terms and conditions. The of
- INSIDEROfficer King-Jones Heidy exercised 28,933 shares at a strike of $14.50 and sold $2,633,902 worth of shares (28,933 units at $91.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Executive Officer Turtle Cameron sold $1,380,105 worth of shares (15,000 units at $92.01) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 537,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Financial Officer Burrows Scott L exercised 25,000 shares at a strike of $14.50 and sold $2,261,831 worth of shares (25,000 units at $90.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 21,424 shares of common stock of Spyre and 6,604 restricted stock units ("RSUs") to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equi
- ANALYSTAnalyst initiated coverage on Spyre Therapeutics with a new price targetAnalyst initiated coverage of Spyre Therapeutics with a rating of Overweight and set a new price target of $110.00
- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRSpyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD CombinationsSPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 20% and endoscopic improvement of 30% SPY003 was well tolerated with a safety profile consistent with the IL-23 class SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYLINE Part B evaluating pairwise combinations of these components is enrolling with topline induction data expected in 2027 WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics,
- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 2,106 shares of common stock of Spyre and 745 restricted stock units ("RSUs") to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Pla
- INSIDEROfficer King-Jones Heidy exercised 28,399 shares at a strike of $14.50 and sold $2,480,529 worth of shares (28,399 units at $87.35) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $2,283,821 worth of shares (25,732 units at $88.75) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 79,762 units (SEC Form 4) (for tax liability)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- INSIDERChief Executive Officer Turtle Cameron sold $1,309,410 worth of shares (15,000 units at $87.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 552,540 units (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- PRSpyre Therapeutics to Participate in Upcoming September Investor ConferencesWALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event: Citi 2026 BioPharma Back to School Conference – New YorkDate: Wednesday, September 9, 2026Fireside Time: 10:00 am ET Event: Wells Fargo 21st Annual Healthcare Conference – BostonDate: Thursday, September 10, 2026Fireside Time: 8:00 am ET Event: Stifel 2026
- SECSpyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
- PRSpyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50) SPY072 was well tolerated with rates of adverse events comparable to placebo Magnitude of effect did not meet the Company’s target to prioritize monotherapy development of SPY072 in rheumatoid arthritis (RA); results support the broad potential of Spyre’s TL1A antibodies in autoimmune disease and as combination components Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spyre Therapeutics Inc.SCHEDULE 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Spyre Therapeutics Inc.SCHEDULE 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
- INSIDERDirector Albers Jeffrey W. exercised 5,000 shares at a strike of $10.39 and sold $2,404,190 worth of shares (23,000 units at $104.53) as part of a pre-agreed trading plan (SEC Form 4)4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
- PRSpyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis SuppurativaSPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT trial designed to provide clinical proof-of-concept for TL1A and IL-17A/F inhibition in Hidradenitis Suppurativa; site activation has begun with topline Week 16 HiSCR75 data planned for late 2027 or early 2028 WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a
- PRSpyre Therapeutics Announces Grants of Inducement AwardsWALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 19,436 shares of common stock of Spyre and 6,186 restricted stock units ("RSUs") to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equ
SYRE FAQ
6 questionsWhere does SYRE stock trade?
Spyre Therapeutics Inc. (SYRE) is listed on NASDAQ.What sector and industry is SYRE in?
Spyre Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spyre Therapeutics Inc. go public?
Spyre Therapeutics Inc. (SYRE) completed its IPO in 2016.What are analysts saying about SYRE?
Spyre Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-10-12. Recent price targets range from $4300.00 to $4500.00.What companies are similar to SYRE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SYRE side-by-side with any of them on Quantisnow.How can I track SYRE on Quantisnow?
Quantisnow aggregates Spyre Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SYRE to receive live email and push alerts on every new disclosure.